Prothena Corp. Plc (PRTA)
9.82
+0.22
(+2.29%)
USD |
NASDAQ |
Sep 04, 16:00
9.80
-0.02
(-0.20%)
After-Hours: 20:00
Prothena Research and Development Expense (Quarterly) : 8.798M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.798M |
| March 31, 2026 | 12.63M |
| December 31, 2025 | 14.59M |
| September 30, 2025 | 28.94M |
| June 30, 2025 | 40.52M |
| March 31, 2025 | 50.81M |
| December 31, 2024 | 50.17M |
| September 30, 2024 | 50.72M |
| June 30, 2024 | 57.51M |
| March 31, 2024 | 64.11M |
| December 31, 2023 | 61.89M |
| September 30, 2023 | 57.91M |
| June 30, 2023 | 56.01M |
| March 31, 2023 | 44.76M |
| December 31, 2022 | 36.87M |
| September 30, 2022 | 39.86M |
| June 30, 2022 | 31.57M |
| March 31, 2022 | 27.26M |
| December 31, 2021 | 22.06M |
| September 30, 2021 | 17.99M |
| June 30, 2021 | 21.09M |
| March 31, 2021 | 21.14M |
| December 31, 2020 | 20.76M |
| September 30, 2020 | 21.60M |
| June 30, 2020 | 17.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.25M |
| December 31, 2019 | 15.47M |
| September 30, 2019 | 12.49M |
| June 30, 2019 | 9.583M |
| March 31, 2019 | 13.30M |
| December 31, 2018 | 16.51M |
| September 30, 2018 | 18.52M |
| June 30, 2018 | 31.45M |
| March 31, 2018 | 34.71M |
| December 31, 2017 | 33.50M |
| September 30, 2017 | 41.32M |
| June 30, 2017 | 34.03M |
| March 31, 2017 | 25.70M |
| December 31, 2016 | 39.84M |
| September 30, 2016 | 26.84M |
| June 30, 2016 | 32.36M |
| March 31, 2016 | 20.49M |
| December 31, 2015 | 17.89M |
| September 30, 2015 | 17.18M |
| June 30, 2015 | 12.79M |
| March 31, 2015 | 10.57M |
| December 31, 2014 | 10.11M |
| September 30, 2014 | 10.39M |
| June 30, 2014 | 8.615M |
| March 31, 2014 | 9.342M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alkermes Plc | 111.12M |
| Amarin Corp. Plc | 4.144M |
| Agenus, Inc. | 14.76M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |